Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 14/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.87 |
| ▸ | POLB | P06746 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601160 | 0.88 | LMNA (0.79) | LMNAMAPTTP53POLB | |
| SCHEMBL26601073 | 0.83 | LMNA (0.83) | LMNAMAPTTP53POLB | |
| SCHEMBL20990665 | 0.83 | LMNA (0.88) | LMNAMAPTTP53POLB | |
| SCHEMBL26601022 | 0.82 | LMNA (0.77) | LMNAMAPTTP53POLB | |
| SCHEMBL26601043 | 0.82 | LMNA (0.77) | LMNAMAPTTP53POLB | |
| SCHEMBL26601176 | 0.82 | LMNA (0.69) | LMNAMAPTTP53POLB | |
| SCHEMBL26601034 | 0.82 | POLB (0.82) | LMNAMAPTTP53POLB | |
| SCHEMBL26601166 | 0.81 | LMNA (0.71) | LMNAMAPTTP53POLB | |
| SCHEMBL26601280 | 0.80 | LMNA (0.69) | LMNAMAPTTP53POLB | |
| SCHEMBL26601117 | 0.79 | LMNA (0.82) | LMNAMAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230285403-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-14 | — | — | US | disclosed |
| US-20230285403-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-14 | — | — | US | disclosed |
| US-11672806-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672806-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210315903-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2021-10-14 | — | — | US | disclosed |
| US-11026950-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200276205-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2020-09-03 | — | — | US | disclosed |
| US-10668078-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190134053-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026950-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | MUC1, MDK, MDN1 | LMNA 1261/4885MAPT 4334/4885TP53 16/4885 |
| US-20230285403-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | MUC1, MDK, EPCAM | LMNA 956/4885MAPT 4130/4885TP53 6/4885 |
| US-20190134053-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | MUC1, MDK, EPCAM | LMNA 956/4885MAPT 4130/4885TP53 6/4885 |
| US-11672806-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | MUC1, MDK, MDN1 | LMNA 1261/4885MAPT 4334/4885TP53 16/4885 |
| US-20200276205-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | MUC1, MDK, EPCAM | LMNA 956/4885MAPT 4130/4885TP53 6/4885 |
| US-10668078-B2 | Methods and compositions for treating mesothelioma and small lung cancer that express midkine | MUC1, MDK, MDN1 | LMNA 1261/4885MAPT 4334/4885TP53 16/4885 |
| US-20210315903-A1 | METHODS AND COMPOSITIONS TO TREAT CANCER | MUC1, MDK, EPCAM | LMNA 956/4885MAPT 4130/4885TP53 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.